BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Authors » Brian Orelli

Brian Orelli

Articles

ARTICLES

IMS Institute: Global drug spending is up on substantial boost from U.S.

Dec. 15, 2014
By Brian Orelli
IMS Institute for Healthcare Informatics is out with its latest prediction for sales of medicines through 2018, when global spending is expected to reach between $1.28 trillion and $1.31 trillion, an increase of $290 million to $320 million over 2013 levels.
Read More

IMS: Global drug spending up on substantial boost from U.S.

Dec. 15, 2014
By Brian Orelli
IMS Institute for Healthcare Informatics is out with its latest prediction for sales of medicines through 2018, when global spending is expected to reach between $1.28 trillion and $1.31 trillion, an increase of $290 million to $320 million over 2013 levels.
Read More

Rana snags industry vet to help develop lncRNA drugs

Dec. 8, 2014
By Brian Orelli
After brokering the sale of Cambridge, Mass.-based Idenix Pharmaceuticals Inc. to Merck & Co. Inc., of Whitehouse Station, N.J., earlier this year, the biotech's former president and CEO, Ronald Renaud, is taking on a new project as CEO of Rana Therapeutics Inc., helping the biotech develop its long noncoding RNA (lncRNA) technology.
Read More

Phosphorous down, iron up in new treatment options for dialysis patients

Nov. 24, 2014
By Brian Orelli
Nephrologists are set to get one and possibly two new drugs in their medicine bag to treat chronic kidney disease (CKD) patients on dialysis.
Read More

Intercept in lead, but many vying for piece of NASH pie

Nov. 17, 2014
By Brian Orelli
We've known that Intercept Pharmaceuticals Inc.'s FLINT trial evaluating obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was positive since the data safety monitoring stopped the trial early for positive efficacy in January. (See BioWorld Today, Jan. 10, 2014.)
Read More

Pharmas team up to develop companion diagnostics

Nov. 10, 2014
By Brian Orelli
Pharma is jumping on the companion diagnostic bandwagon with both feet.
Read More

Late-stage deals up in Q3; reformulations lead the way

Nov. 3, 2014
By Brian Orelli
According to calculations by Morrison & Foerster LLP's Biometer, the average up-front payment for biotech deals in the third quarter came in at $43.7 million, up from $30.4 million in the year-ago quarter.
Read More

CRO-sponsor partnerships require planning, time to develop

Oct. 27, 2014
By Brian Orelli
A report from Tufts Center for the Study of Drug Development (CSDD) highlights the evolving relationships between contract research organizations (CROs) and clinical trial sponsors through the adoption of strategic partnerships.
Read More

Gene therapy enters next phase, still faces plenty of challenges

Oct. 13, 2014
By Brian Orelli
LA JOLLA, Calif. – Gene therapy has come a long way from using retroviral vectors to insert gamma-chain transgenes into cells of children with severe combined immunodeficiency in the early 1990s, an act that increased the risk of developing leukemia.
Read More

Stem cell treatments face reimbursement challenges: Panel

Oct. 9, 2014
By Brian Orelli
LA JOLLA, Calif. – Stem cells offer promising new treatments, but panelists at a session during the annual Stem Cell Meeting on the Mesa warned the audience that the treatments' unique features pose challenges to gaining reimbursement.
Read More
View All Articles by Brian Orelli

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing